EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 206 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Lung cancer screening can’t leave anyone in the UK behind July 27, 2023 Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with... December 18, 2025 Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced... September 4, 2025 Επικοινωνία January 18, 2019 Load more HOT NEWS Teacher Reads To Students One Day After Having Brain Surgery Factors Associated with COVID-19 Severity Among Patients with Cancer Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent... Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas
